Fig. 5
From: OTUB1 promotes osteoblastic bone formation through stabilizing FGFR2
FGFR2 rescues OTUB1 deletion-caused bone mass loss and osteogenesis defects. a Schematic representation of experimental design of adeno-associated virus serotype 9 (AAV9)-delivered Fgfr2 treatment in mice. b AAV9-FGFR2 expression in the hindlimb was monitored by IVIS-100 optical imaging 2 months post injection. Scale bars, 1 cm. c Quantitative RT-PCR analysis of Fgfr2 mRNA levels in humeral diaphysis from OTUB1 CTRL, CKO, and CKO with injection of AAV9-FGFR2 groups after 2 months. n = 5 per group. d Representative micro-CT images of whole femoral (top) and trabecular (bottom) bones from OTUB1 CTRL, CKO, and CKO with injection of AAV9-FGFR2 groups after 2 months. n = 5 per group. Scale bars, 0.5 mm. e Histomorphometric analysis of trabecular bones in (d), including BMD, BV/TV, Tb.Th, Tb.N, Tb.Sp, and cortical density. n = 5 per group. f Quantitative RT-PCR analysis of osteogenesis genes mRNA levels in femurs from OTUB1 CTRL, CKO, and CKO with injection of AAV9-FGFR2 groups after 2 months. n = 5 per group. g Quantitative RT-PCR analysis of osteoclastogenesis genes mRNA levels in femurs from OTUB1 CTRL, CKO, and CKO with injection of AAV9-FGFR2 groups after 2 months. n = 5 per group. h Quantitative analysis of N.Ob/BS in femurs from OTUB1 CTRL, CKO, and CKO with injection of AAV9-FGFR2 groups. n = 4 per group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n.s., not significant. All data are shown as the mean ± SEM
